0000064803false00000648032024-11-062024-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):November 6, 2024
cvshealtha38.jpg
CVS HEALTH CORPORATION
(Exact name of registrant as specified in its charter)
Delaware001-0101105-0494040
(State or other jurisdiction of incorporation)(Commission
File Number)		(IRS Employer
Identification No.)

One CVS Drive, Woonsocket, Rhode Island        02895
(Address of principal executive offices)            (Zip Code)

Registrant’s telephone number, including area code:         (401) 765-1500
Former name or former address, if changed since last report:    N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCVSNew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐




Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2024, CVS Health Corporation issued a press release announcing results for the three months ended September 30, 2024. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.

The information in this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d)        Exhibits.

The exhibits to this Current Report on Form 8-K are as follows:

INDEX TO EXHIBITS

99.1
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


CVS HEALTH CORPORATION
Date:November 6, 2024By:/s/ Thomas F. Cowhey
Thomas F. Cowhey
Executive Vice President and Chief Financial Officer



a81cvs_healthxlogoxhxregxra.jpg     Exhibit 99.1

CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS
Financial Highlights
•Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior year
•Third quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09
•Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segment
•Generated year-to-date cash flow from operations of $7.2 billion
CEO Commentary
“Our integrated model accelerates our ability to uniquely do what is most important to today’s health care consumers: deliver lower cost of care, a simpler experience and better outcomes. Our third quarter results reflect strong performance in the Health Services and Pharmacy & Consumer Wellness segments, and also highlight the continued need to work across our enterprise and address macro challenges to the Health Care Benefits segment. My commitment to our CVS Health colleagues and our customers is to drive focused execution of our integrated strategy to improve the health of the 185 million people we are privileged to serve.”
— David Joyner, CVS Health President and CEO

WOONSOCKET, RHODE ISLAND, November 6, 2024 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months ended September 30, 2024.
Financial Results Summary
Three Months Ended
September 30,
In millions, except per share amounts20242023Change
Total revenues
$95,428 $89,764 $5,664 
Operating income832 3,690 (2,858)
Adjusted operating income (1)
2,547 4,456 (1,909)
Diluted earnings per share $0.07 $1.75 $(1.68)
Adjusted EPS (2)
$1.09 $2.21 $(1.12)

Third quarter GAAP diluted EPS of $0.07 decreased from $1.75 in the prior year and Adjusted EPS of $1.09 decreased from $2.21 in the prior year, primarily due to a decline in the Health Care Benefits segment’s operating results, which reflect continued utilization pressure and premium deficiency reserves of approximately $1.1 billion recorded in the third quarter of 2024, related to anticipated losses in the fourth quarter of 2024 within the Medicare and individual exchange product lines. The premium deficiency reserves are expected to be substantially released during the fourth quarter of 2024, benefiting results in that period.


Investor Contact: Larry McGrath | Executive Vice President, Chief Strategy Officer and Chief Strategic Advisor to the CEO | (800) 201-0938
Media Contact: Ethan Slavin | Executive Director, Corporate Communications | (860) 273-6095

The Company presents both GAAP and non-GAAP financial measures in this press release to assist in the comparison of the Company’s past financial performance with its current financial performance. See “Non-GAAP Financial Information” beginning on page 11 and endnotes beginning on page 22 for explanations of non-GAAP financial measures presented in this press release. See pages 13 through 15 for reconciliations of each non-GAAP financial measure used in this release to the most directly comparable GAAP financial measure.
1

Consolidated third quarter results
Three Months Ended
September 30,		Nine Months Ended
September 30,
In millions, except per share amounts20242023Change20242023Change
Total revenues
$95,428 $89,764 $5,664 $275,099 $263,963 $11,136 
Operating income
832 3,690 (2,858)6,148 10,370 (4,222)
Adjusted operating income (1)
2,547 4,456 (1,909)9,248 13,307 (4,059)
Net income
71 2,265 (2,194)2,963 6,321 (3,358)
Diluted earnings per share$0.07 $1.75 $(1.68)$2.35 $4.88 $(2.53)
Adjusted EPS (2)
$1.09 $2.21 $(1.12)$4.23 $6.62 $(2.39)
For the three months ended September 30, 2024 compared to the prior year:
•Total revenues increased 6.3% primarily driven by growth in the Health Care Benefits and Pharmacy & Consumer Wellness segments, partially offset by a decline in the Health Services segment.
•Operating income decreased 77.5% primarily due to the decrease in adjusted operating income described below and restructuring charges of approximately $1.2 billion recorded in the current year.
•Adjusted operating income decreased 42.8% driven by a decline in the Health Care Benefits segment, primarily due to increased utilization and premium deficiency reserves recorded in the third quarter of 2024 related to anticipated losses in the fourth quarter of 2024, partially offset by increases in the Health Services and Pharmacy & Consumer Wellness segments. See pages 3 through 5 for additional discussion of the adjusted operating income performance of the Company’s segments.
•Interest expense increased $59 million, or 8.5%, due to higher debt in the three months ended September 30, 2024, primarily driven by long-term debt issued in May 2024.
•The effective income tax rate increased to 32.4% compared to 25.0% primarily due to lower pre-tax income in the three months ended September 30, 2024 compared to the prior year.

Restructuring program
•During the third quarter of 2024, the Company finalized an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, during the three months ended September 30, 2024, the Company recorded restructuring charges of approximately $1.2 billion, comprised of a $607 million store impairment charge for additional retail pharmacy stores it plans to close in 2025, $293 million of costs associated with corporate workforce optimization, including severance and employee-related costs, and $269 million of other asset impairments and related charges associated with the discontinuation of certain non-core assets.
2

Health Care Benefits segment

The Health Care Benefits segment offers a full range of insured and self-insured (“ASC”) medical, pharmacy, dental and behavioral health products and services. The segment results for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
In millions, except percentages20242023Change20242023Change
Total revenues$32,996$26,296$6,700$97,707$78,920$18,787
Adjusted operating income (loss) (1)
(924)1,536(2,460)7464,901(4,155)
Medical benefit ratio (“MBR”) (3)
95.2 %85.7 %9.5 %91.7 %85.5 %6.2 %
Medical membership (4)
27.125.71.4
            
•Total revenues increased 25.5% for the three months ended September 30, 2024 compared to the prior year driven by growth in the Medicare and Commercial product lines.
•During the third quarter of 2024, the Company recorded premium deficiency reserves of approximately $1.1 billion, primarily in its Medicare and individual exchange product lines related to anticipated losses for the 2024 coverage year. The $1.1 billion premium deficiency recorded was comprised of $394 million of operating expenses related to the write-off of unamortized acquisition costs and $670 million of health care costs.
•During the three months ended September 30, 2024, the Health Care Benefits segment had an adjusted operating loss of $924 million compared to adjusted operating income of $1.5 billion in the prior year. The change was primarily driven by increased utilization, the approximately $1.1 billion of premium deficiency reserves described above, the impact of higher acuity in Medicaid following the resumption of redeterminations and the unfavorable impact of the previously disclosed decline in the Company’s Medicare Advantage star ratings for the 2024 payment year. These decreases were partially offset by an increase in net investment income.
•The MBR increased to 95.2% in the three months ended September 30, 2024 compared to 85.7% in the prior year driven by increased utilization, the $670 million (220 basis points) of premium deficiency reserves recorded as health care costs described above, higher acuity in Medicaid and the unfavorable impact of the Company’s Medicare Advantage star ratings for the 2024 payment year.
•Medical membership as of September 30, 2024 of 27.1 million increased 178,000 members compared with June 30, 2024, reflecting increases in the Commercial and Medicare product lines.
•Prior years’ health care costs payable estimates developed favorably by $788 million during the nine months ended September 30, 2024. This development is reported on a basis consistent with the prior years’ development reported in the health care costs payable table in the Company’s annual audited financial statements and does not directly correspond to an increase in 2024 operating results.
•Days claims payable were 44.6 days as of September 30, 2024, a increase of 1.5 days compared to June 30, 2024. The increase was primarily driven by the impact of the premium deficiency reserves recorded as health care costs in the third quarter of 2024 described above.
•The U.S. Centers for Medicare & Medicaid Services (“CMS”) released the Company’s 2025 star ratings in October 2024. The Company’s 2025 star ratings will be used to determine which of the Company’s Medicare Advantage plans have ratings of four stars or higher and qualify for bonus payments in 2026. Based on the Company’s membership as of September 2024, 88% of the Company’s Medicare Advantage members were in plans with 2025 star ratings of at least 4.0 stars, compared to 87% of the Company’s Medicare Advantage members being in plans with 2024 star ratings of at least 4.0 stars based on the Company’s membership as of September 2023.

See the supplemental information on page 17 for additional information regarding the performance of the Health Care Benefits segment.
3

Health Services segment

The Health Services segment provides a full range of pharmacy benefit management solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The segment results for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
In millions20242023Change20242023Change
Total revenues$44,129 $46,891 $(2,762)$126,585 $137,697 $(11,112)
Adjusted operating income (1)
2,204 1,878 326 5,482 5,452 30 
Pharmacy claims processed (5) (6)
484.1 579.6 (95.5)1,418.2 1,743.5 (325.3)
    
•Total revenues decreased 5.9% for the three months ended September 30, 2024 compared to the prior year primarily driven by the previously announced loss of a large client and continued pharmacy client price improvements. These decreases were partially offset by pharmacy drug mix, increased contributions from the Company’s health care delivery assets and growth in specialty pharmacy.
•Adjusted operating income increased 17.4% for the three months ended September 30, 2024 compared to the prior year primarily driven by improved purchasing economics, partially offset by continued pharmacy client price improvements and the previously announced loss of a large client.
•Pharmacy claims processed decreased 16.5% on a 30-day equivalent basis for the three months ended September 30, 2024 compared to the prior year, reflecting the previously announced loss of a large client.

See the supplemental information on page 18 for additional information regarding the performance of the Health Services segment.
4

Pharmacy & Consumer Wellness segment

The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. The segment also provides pharmacy services to long-term care facilities and pharmacy fulfillment services to support the Health Services segment’s specialty and mail order pharmacy offerings. The segment results for the three and nine months ended September 30, 2024 and 2023 were as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
In millions20242023Change20242023Change
Total revenues$32,423 $28,872 $3,551 $90,986 $85,578 $5,408 
Adjusted operating income (1)
1,596 1,389 207 4,016 3,936 80 
Prescriptions filled (5) (6)
431.6 407.1 24.5 1,269.6 1,217.6 52.0 
        
•Total revenues increased 12.3% for the three months ended September 30, 2024 compared to the prior year primarily driven by increased prescription volume, including increased contributions from vaccinations, and pharmacy drug mix. These increases were partially offset by continued pharmacy reimbursement pressure, the impact of recent generic introductions and decreased front store volume, including the impact of a decrease in store count.
•Adjusted operating income increased 14.9% for the three months ended September 30, 2024 compared to the prior year primarily driven by increased prescription volume, including increased contributions from vaccinations, as well as improved drug purchasing. These increases were partially offset by continued pharmacy reimbursement pressure and decreased front store volume in the three months ended September 30, 2024.
•Prescriptions filled increased 6.0% on a 30-day equivalent basis for the three months ended September 30, 2024 compared to the prior year primarily driven by increased utilization.
•Same store prescription volume(6)(12) increased 9.1% on a 30-day equivalent basis for the three months ended September 30, 2024 compared to the prior year.

See the supplemental information on page 19 for additional information regarding the performance of the Pharmacy & Consumer Wellness segment.
5

Teleconference and webcast

The Company will be holding a conference call today for investors at 8:00 a.m. (Eastern Time) to discuss its third quarter results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com. This webcast will be archived and available on the website for a one-year period following the conference call.

About CVS Health

CVS Health is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that’s managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media.

Cautionary statement concerning forward-looking statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, the information under the headings “CEO Commentary” and “Financial Results Summary” and the information included in the reconciliations and endnotes. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2024, June 30, 2024 and September 30, 2024 and our Current Reports on Form 8-K.

You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.
- Tables Follow -

6

CVS HEALTH CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
September 30,		Nine Months Ended
September 30,
In millions, except per share amounts2024202320242023
Revenues:
Products$59,674 $61,298 $169,610 $179,984 
Premiums30,925 24,657 91,983 74,117 
Services4,279 3,532 12,108 8,977 
Net investment income550 277 1,398 885 
Total revenues95,428 89,764 275,099 263,963 
Operating costs:
Cost of products sold52,948 54,688 151,019 159,679 
Health care costs29,922 21,499 85,578 63,729 
Operating expenses10,557 9,876 31,185 29,329 
Restructuring charges
1,169 11 1,169 507 
Loss on assets held for sale— — — 349 
Total operating costs94,596 86,074 268,951 253,593 
Operating income
832 3,690 6,148 10,370 
Interest expense752 693 2,200 1,968 
Other income(25)(22)(74)(66)
Income before income tax provision
105 3,019 4,022 8,468 
Income tax provision
34 754 1,059 2,147 
Net income
71 2,265 2,963 6,321 
Net (income) loss attributable to noncontrolling interests16 (4)7 (23)
Net income attributable to CVS Health$87 $2,261 $2,970 $6,298 
Net income per share attributable to CVS Health:
Basic$0.07 $1.76 $2.36 $4.90 
Diluted$0.07 $1.75 $2.35 $4.88 
Weighted average shares outstanding:
Basic1,259 1,287 1,258 1,284 
Diluted1,259 1,290 1,262 1,289 
Dividends declared per share$0.665 $0.605 $1.995 $1.815 

7

CVS HEALTH CORPORATION
Condensed Consolidated Balance Sheets
(Unaudited)
In millionsSeptember 30,
2024		December 31,
2023
Assets:
Cash and cash equivalents$6,875 $8,196 
Investments2,805 3,259 
Accounts receivable, net36,179 35,227 
Inventories17,649 18,025 
Other current assets3,835 3,151 
Total current assets67,343 67,858 
Long-term investments28,939 23,019 
Property and equipment, net12,728 13,183 
Operating lease right-of-use assets16,231 17,252 
Goodwill91,272 91,272 
Intangible assets, net27,817 29,234 
Separate accounts assets3,334 3,250 
Other assets4,763 4,660 
Total assets$252,427 $249,728 
Liabilities:
Accounts payable$15,713 $14,897 
Pharmacy claims and discounts payable23,917 22,874 
Health care costs payable 15,237 12,049 
Policyholders’ funds913 1,326 
Accrued expenses20,174 22,189 
Other insurance liabilities1,051 1,141 
Current portion of operating lease liabilities1,912 1,741 
Short-term debt800 200 
Current portion of long-term debt4,910 2,772 
Total current liabilities84,627 79,189 
Long-term operating lease liabilities15,258 16,034 
Long-term debt59,824 58,638 
Deferred income taxes3,632 4,311 
Separate accounts liabilities3,334 3,250 
Other long-term insurance liabilities5,162 5,459 
Other long-term liabilities5,484 6,211 
Total liabilities177,321 173,092 
Shareholders’ equity:
Preferred stock— — 
Common stock and capital surplus49,510 48,992 
Treasury stock(36,813)(33,838)
Retained earnings62,038 61,604 
Accumulated other comprehensive income (loss)
209 (297)
Total CVS Health shareholders’ equity74,944 76,461 
Noncontrolling interests162 175 
Total shareholders’ equity75,106 76,636 
Total liabilities and shareholders’ equity$252,427 $249,728 

8

CVS HEALTH CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Nine Months Ended
September 30,
In millions20242023
Cash flows from operating activities:
Cash receipts from customers$264,538 $260,300 
Cash paid for inventory, prescriptions dispensed and health services rendered(145,469)(153,051)
Insurance benefits paid (80,357)(61,658)
Cash paid to other suppliers and employees(28,933)(26,038)
Interest and investment income received1,288 1,174 
Interest paid(2,391)(2,049)
Income taxes paid(1,429)(2,616)
Net cash provided by operating activities7,247 16,062 
Cash flows from investing activities:
Proceeds from sales and maturities of investments7,634 5,547 
Purchases of investments(12,677)(6,625)
Purchases of property and equipment(2,013)(2,120)
Acquisitions (net of cash and restricted cash acquired)(85)(16,492)
Other75 43 
Net cash used in investing activities(7,066)(19,647)
Cash flows from financing activities:
Commercial paper borrowings (repayments), net600 — 
Proceeds from issuance of short-term loan— 5,000 
Repayment of short-term loan— (5,000)
Proceeds from issuance of long-term debt4,959 10,898 
Repayments of long-term debt(1,706)(2,734)
Repurchase of common stock(3,023)(2,013)
Dividends paid(2,535)(2,353)
Proceeds from exercise of stock options342 242 
Payments for taxes related to net share settlement of equity awards(181)(175)
Other(22)(210)
Net cash provided by (used in) financing activities
(1,566)3,655 
Net increase (decrease) in cash, cash equivalents and restricted cash
(1,385)70 
Cash, cash equivalents and restricted cash at the beginning of the period8,525 13,305 
Cash, cash equivalents and restricted cash at the end of the period$7,140 $13,375 

9

CVS HEALTH CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)

Nine Months Ended
September 30,
In millions20242023
Reconciliation of net income to net cash provided by operating activities:
Net income$2,963 $6,321 
Adjustments required to reconcile net income to net cash provided by operating activities:
Depreciation and amortization3,450 3,232 
Stock-based compensation403 461 
Restructuring charges (impairment of long-lived assets)
840 152 
Deferred income taxes and other items(912)(163)
Change in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable, net(986)(3,920)
Inventories355 1,305 
Other assets(850)(518)
Accounts payable and pharmacy claims and discounts payable2,169 2,466 
Health care costs payable and other insurance liabilities2,878 4,679 
Other liabilities(3,063)2,047 
Net cash provided by operating activities$7,247 $16,062 

10

Non-GAAP Financial Information

The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current and expected future performance. These non-GAAP financial measures, which are included in this press release and which may be referred to on the conference call discussing the Company’s third quarter financial results, are provided as supplemental information to the financial measures presented in this press release and discussed on the conference call that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies.

Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share (“EPS”) and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance.

For the periods covered in this press release, the following items are excluded from the non-GAAP financial measures described above, as applicable, because the Company believes they neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance:
•The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the unaudited condensed consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
•The Company’s net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in the unaudited condensed consolidated statements of operations in net investment income (loss) within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company’s business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends.
•During the three and nine months ended September 30, 2024, the acquisition-related integration costs relate to the acquisitions of Signify Health and Oak Street Health. During the three and nine months ended September 30, 2023, the acquisition-related transaction and integration costs relate to the acquisitions of Signify Health and Oak Street Health. The acquisition-related transaction and integration costs are reflected in the
11

Company’s unaudited condensed consolidated statements of operations in operating expenses within the Corporate/Other segment.
•During the three and nine months ended September 30, 2024, the restructuring charges are primarily comprised of a store impairment charge, corporate workforce optimization costs, including severance and employee-related costs, and other asset impairment and related charges associated with the discontinuation of certain non-core assets. During the third quarter of 2024, the Company finalized an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, the Company completed a strategic review of its retail business and determined that it plans to close additional retail stores in 2025, and, accordingly, it recorded a store impairment charge to write down the associated operating lease right-of-use assets and property and equipment. In addition, during the third quarter of 2024, the Company also conducted a review of its various strategic assets and determined that it would discontinue the use of certain non-core assets, at which time impairment losses were recorded to write down the carrying value of these assets to the Company’s best estimate of their fair value. During the three months ended September 30, 2023, the restructuring charges are primarily comprised of a stock-based compensation charge. During the nine months ended September 30, 2023, the restructuring charges also include severance and employee-related costs and asset impairment charges. The restructuring charges associated with the store impairments are reflected within the Pharmacy & Consumer Wellness segment, other asset impairments and related charges are reflected within the Corporate/Other and Pharmacy & Consumer Wellness segments and corporate workforce optimization costs are reflected within the Corporate/Other segment.
•During the three and nine months ended September 30, 2024 and 2023, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company’s continuous evaluation of corporate office real estate space in response to its ongoing flexible work arrangement. The office real estate optimization charges are reflected in the Company’s unaudited condensed consolidated statements of operations in operating expenses within each segment.
•During the nine months ended September 30, 2024, the opioid litigation charge relates to a change in the Company’s accrual related to ongoing opioid litigation matters.
•During the nine months ended September 30, 2023, the loss on assets held for sale relates to the long-term care (“LTC”) reporting unit within the Pharmacy & Consumer Wellness segment. During 2022, the Company determined that its LTC business was no longer a strategic asset and committed to a plan to sell it, at which time the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. During the first quarter of 2023, a loss on assets held for sale was recorded to write down the carrying value of the LTC business to the Company’s best estimate of the ultimate selling price which reflected its estimated fair value less costs to sell. As of the third quarter of 2023, the Company determined the LTC business no longer met the criteria for held-for-sale accounting and accordingly the net assets associated with the LTC business were reclassified to held and used at their respective fair values.
•The corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.

See endnotes (1) and (2) on page 22 for definitions of non-GAAP financial measures. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented on pages 13 through 15.
12

Reconciliations of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures

Adjusted Operating Income
(Unaudited)

The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income (loss) to segment adjusted operating income (loss):
Three Months Ended September 30, 2024
In millionsHealth Care
Benefits		Health
Services		Pharmacy &
Consumer
Wellness		Corporate/
Other		Consolidated
Totals
Operating income (loss) (GAAP measure)$(1,229)$2,055 $784 $(778)$832 
Amortization of intangible assets294 149 64 — 507 
Net realized capital (gains) losses
1 — — (20)(19)
Acquisition-related integration costs— — — 41 41 
Restructuring charges
— — 747 422 1,169 
Office real estate optimization charges10 — 1 6 17 
Adjusted operating income (loss) (1)
$(924)$2,204 $1,596 $(329)$2,547 

Three Months Ended September 30, 2023
In millionsHealth Care
Benefits		Health
Services		Pharmacy &
Consumer
Wellness		Corporate/
Other		Consolidated
Totals
Operating income (loss) (GAAP measure)$1,115 $1,727 $1,322 $(474)$3,690 
Amortization of intangible assets294 150 65 — 509 
Net realized capital losses
119 — 2 21 142 
Acquisition-related transaction and
integration costs		— — — 94 94 
Restructuring charges— — — 11 11 
Office real estate optimization charges8 1 — 1 10 
Adjusted operating income (loss) (1)
$1,536 $1,878 $1,389 $(347)$4,456 
13

Nine Months Ended September 30, 2024
In millionsHealth Care
Benefits		Health
Services		Pharmacy &
Consumer
Wellness		Corporate/
Other		Consolidated
Totals
Operating income (loss) (GAAP measure)
$(227)$5,034 $3,076 $(1,735)$6,148 
Amortization of intangible assets881 448 192 1 1,522 
Net realized capital losses
82 — — 7 89 
Acquisition-related integration costs
— — — 203 203 
Restructuring charges
— — 747 422 1,169 
Office real estate optimization charges10 — 1 6 17 
Opioid litigation charge
— — — 100 100 
Adjusted operating income (loss) (1)
$746 $5,482 $4,016 $(996)$9,248 

Nine Months Ended September 30, 2023
In millionsHealth Care
Benefits		Health
Services		Pharmacy &
Consumer
Wellness		Corporate/
Other		Consolidated
Totals
Operating income (loss) (GAAP measure)$3,683 $5,132 $3,388 $(1,833)$10,370 
Amortization of intangible assets883 316 195 2 1,396 
Net realized capital losses296 — 4 45 345 
Acquisition-related transaction and integration costs— — — 294 294 
Restructuring charges
— — — 507 507 
Office real estate optimization charges39 4 — 3 46 
Loss on assets held for sale— — 349 — 349 
Adjusted operating income (loss) (1)
$4,901 $5,452 $3,936 $(982)$13,307 
14

Adjusted Earnings Per Share
(Unaudited)

The following are reconciliations of net income attributable to CVS Health to adjusted income attributable to CVS Health and calculations of GAAP diluted EPS and Adjusted EPS:
Three Months Ended
September 30, 2024		Three Months Ended
September 30, 2023
In millions, except per share amountsTotal
Company		Per
Common
Share		Total
Company		Per
Common
Share
Net income attributable to CVS Health (GAAP measure)$87 $0.07 $2,261 $1.75 
Amortization of intangible assets507 0.40 509 0.39 
Net realized capital (gains) losses
(19)(0.02)142 0.11 
Acquisition-related transaction and integration costs41 0.03 94 0.07 
Restructuring charges
1,169 0.93 11 0.01 
Office real estate optimization charges17 0.01 10 0.01 
Tax impact of non-GAAP adjustments(433)(0.33)(177)(0.13)
Adjusted income attributable to CVS Health (2)
$1,369 $1.09 $2,850 $2.21 
Weighted average diluted shares outstanding1,259 1,290 

Nine Months Ended
September 30, 2024		Nine Months Ended
September 30, 2023
In millions, except per share amountsTotal
Company		Per
Common
Share		Total
Company		Per
Common
Share
Net income attributable to CVS Health (GAAP measure)
$2,970 $2.35 $6,298 $4.88 
Amortization of intangible assets1,522 1.21 1,396 1.08 
Net realized capital losses
89 0.07 345 0.27 
Acquisition-related transaction and integration costs203 0.16 294 0.23 
Restructuring charges
1,169 0.93 507 0.39 
Office real estate optimization charges17 0.01 46 0.04 
Opioid litigation charge100 0.08 — — 
Loss on assets held for sale— — 349 0.27 
Tax impact of non-GAAP adjustments(738)(0.58)(701)(0.54)
Adjusted income attributable to CVS Health (2)
$5,332 $4.23 $8,534 $6.62 
Weighted average diluted shares outstanding
1,262 1,289 

15

Supplemental Information
(Unaudited)

The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income. Adjusted operating income is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance as further described in endnote (1). The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM’s ability to compare past financial performance with current performance and analyze underlying business performance and trends.

The following are reconciliations of financial measures of the Company’s segments to the consolidated totals:
In millionsHealth Care
Benefits
Health
Services (a)
Pharmacy &
Consumer
Wellness		Corporate/
Other
Intersegment
Eliminations (b)
Consolidated
Totals
Three Months Ended
September 30, 2024
Total revenues$32,996 $44,129 $32,423 $142 $(14,262)$95,428 
Adjusted operating income (loss) (1)
(924)2,204 1,596 (329)— 2,547 
September 30, 2023
Total revenues$26,296 $46,891 $28,872 $105 $(12,400)$89,764 
Adjusted operating
income (loss) (1)
1,536 1,878 1,389 (347)— 4,456 
Nine Months Ended
September 30, 2024
Total revenues$97,707 $126,585 $90,986 $368 $(40,547)$275,099 
Adjusted operating income (loss) (1)
746 5,482 4,016 (996)— 9,248 
September 30, 2023
Total revenues$78,920 $137,697 $85,578 $376 $(38,608)$263,963 
Adjusted operating income (loss) (1)
4,901 5,452 3,936 (982)— 13,307 
_____________________________________________
(a)Total revenues of the Health Services segment include approximately $2.7 billion and $3.2 billion of retail co-payments for the three months ended September 30, 2024 and 2023, respectively, and $8.9 billion and $10.7 billion of retail co-payments for the nine months ended September 30, 2024 and 2023, respectively.
(b)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment.
 
16

Supplemental Information
(Unaudited)

Health Care Benefits segment

The following table summarizes the Health Care Benefits segment’s performance for the respective periods:
Change
Three Months Ended
September 30,		Nine Months Ended
September 30,		Three Months Ended
September 30,
2024 vs 2023		Nine Months Ended
September 30,
2024 vs 2023
In millions, except percentages and basis points (“bps”)2024202320242023$%$%
Revenues:
Premiums$30,914$24,645$91,947$74,079$6,269 25.4 %$17,868 24.1 %
Services1,6591,4644,6844,285195 13.3 %399 9.3 %
Net investment income4231871,076556236 126.2 %520 93.5 %
Total revenues32,99626,29697,70778,9206,700 25.5 %18,787 23.8 %
Health care costs29,44321,11484,35963,3298,329 39.4 %21,030 33.2 %
MBR (Health care costs as a % of premium revenues) (3)
95.2 %85.7 %91.7 %85.5 %950 bps620 bps
Operating expenses$4,782$4,067$13,575$11,908$715 17.6 %$1,667 14.0 %
Operating expenses as a % of total revenues14.5 %15.5 %13.9 %15.1 %
Operating income (loss)
$(1,229)$1,115$(227)$3,683$(2,344)(210.2)%$(3,910)(106.2)%
Operating income (loss) as a % of total revenues
(3.7)%4.2 %(0.2)%4.7 %
Adjusted operating income (loss) (1)
$(924)$1,536$746$4,901$(2,460)(160.2)%$(4,155)(84.8)%
Adjusted operating income (loss) as a % of total revenues
(2.8)%5.8 %0.8 %6.2 %
Premium revenues (by business):
Government$22,331$17,208$66,269$52,680$5,123 29.8 %$13,58925.8 %
Commercial8,5837,43725,67821,3991,146 15.4 %4,279 20.0 %

The following table summarizes the Health Care Benefits segment’s medical membership for the respective periods:
September 30, 2024June 30, 2024December 31, 2023September 30, 2023
In thousandsInsuredASCTotalInsuredASCTotalInsuredASCTotalInsuredASCTotal
Medical membership: (4)
Commercial4,751 14,155 18,906 4,702 14,099 18,801 4,252 14,087 18,339 4,198 14,075 18,273 
Medicare Advantage4,438 — 4,438 4,342 — 4,342 3,460 — 3,460 3,438 — 3,438 
Medicare Supplement1,291 — 1,291 1,294 — 1,294 1,343 — 1,343 1,352 — 1,352 
Medicaid2,077 436 2,513 2,090 443 2,533 2,073 444 2,517 2,173 452 2,625 
Total medical membership12,557 14,591 27,148 12,428 14,542 26,970 11,128 14,531 25,659 11,161 14,527 25,688 
Supplemental membership information:
Medicare Prescription Drug Plan (stand-alone)4,898 4,903 6,081 6,092 

The following table summarizes the Health Care Benefits segment’s days claims payable for the respective periods:
September 30, 2024June 30, 2024March 31, 2024December 31, 2023September 30, 2023
Days Claims Payable (7)
44.6 43.1 44.5 45.9 50.3 
17

Supplemental Information
(Unaudited)

Health Services segment

The following table summarizes the Health Services segment’s performance for the respective periods:
Change
Three Months Ended
September 30,		Nine Months Ended
September 30,		Three Months Ended
September 30,
2024 vs 2023		Nine Months Ended
September 30,
2024 vs 2023
In millions, except percentages2024202320242023$%$%
Revenues:
Products$41,208$45,019$118,417$133,371$(3,811)(8.5)%$(14,954)(11.2)%
Services2,9221,8728,1714,3261,050 56.1 %3,845 88.9 %
Net investment income (loss)(1)—(3)—(1)(100.0)%(3)(100.0)%
Total revenues44,12946,891126,585137,697(2,762)(5.9)%(11,112)(8.1)%
Cost of products sold40,38143,738116,678129,425(3,357)(7.7)%(12,747)(9.8)%
Health care costs9366122,428995324 52.9 %1,433 144.0 %
Gross profit (8)
2,8122,5417,4797,277271 10.7 %202 2.8 %
Gross margin (Gross profit as a % of total revenues) (8)
6.4 %5.4 %5.9 %5.3 %
Operating expenses$757$814$2,445$2,145$(57)(7.0)%$300 14.0 %
Operating expenses as a % of total revenues1.7 %1.7 %1.9 %1.6 %
Operating income
$2,055$1,727$5,034$5,132$328 19.0 %$(98)(1.9)%
Operating income as a % of total revenues4.7 %3.7 %4.0 %3.7 %
Adjusted operating income (1)
$2,204$1,878$5,482$5,452$326 17.4 %$30 0.6 %
Adjusted operating income as a % of total revenues5.0 %4.0 %4.3 %4.0 %
Revenues (by distribution channel):
Pharmacy network (9)
$24,136$27,981$66,448$83,050$(3,845)(13.7)%$(16,602)(20.0)%
Mail & specialty (10)
17,21417,00452,12750,378210 1.2 %1,749 3.5 %
Other 2,7801,9068,0134,269874 45.9 %3,744 87.7 %
Net investment income (loss)(1)—(3)—(1)(100.0)%(3)(100.0)%
Pharmacy claims processed (5) (6)
484.1579.61,418.21,743.5(95.5)(16.5)%(325.3)(18.7)%
Generic dispensing rate (6) (11)
86.8 %87.5 %87.8 %88.1 %
18

Supplemental Information
(Unaudited)

Pharmacy & Consumer Wellness segment

The following table summarizes the Pharmacy & Consumer Wellness segment’s performance for the respective periods:
Change
Three Months Ended
September 30,		Nine Months Ended
September 30,		Three Months Ended
September 30,
2024 vs 2023		Nine Months Ended
September 30,
2024 vs 2023
In millions, except percentages2024202320242023$%$%
Revenues:
Products$31,823$28,043$89,195$83,442$3,780 13.5 %$5,753 6.9 %
Services6008311,7912,140(231)(27.8)%(349)(16.3)%
Net investment income (loss)—(2)—(4)2 100.0 %4 100.0 %
Total revenues32,42328,87290,98685,5783,551 12.3 %5,408 6.3 %
Cost of products sold26,03222,79772,62767,3013,235 14.2 %5,326 7.9 %
Gross profit (8)
6,3916,07518,35918,277316 5.2 %82 0.4 %
Gross margin (Gross profit as a % of total revenues) (8)
19.7 %21.0 %20.2 %21.4 %
Operating expenses $4,860$4,753$14,536$14,540$107 2.3 %$(4)— %
Operating expenses as a % of total revenues15.0 %16.5 %16.0 %17.0 %
Restructuring charge
$747$— $747$— $747 100.0 %$747 100.0 %
Loss on assets held for sale—— —349 — — %(349)(100.0)%
Operating income7841,3223,0763,388(538)(40.7)%(312)(9.2)%
Operating income as a % of total revenues2.4 %4.6 %3.4 %4.0 %
Adjusted operating income (1)
$1,596$1,389$4,016$3,936$207 14.9 %$80 2.0 %
Adjusted operating income as a % of total revenues4.9 %4.8 %4.4 %4.6 %
Revenues (by major goods/service lines):
Pharmacy$26,666$22,977$73,463$67,371$3,689 16.1 %$6,092 9.0 %
Front Store 5,1965,37115,84716,597(175)(3.3)%(750)(4.5)%
Other5615261,6761,61435 6.7 %62 3.8 %
Net investment income (loss)—(2)—(4)2 100.0 %4 100.0 %
Prescriptions filled (5) (6)
431.6407.11,269.61,217.624.5 6.0 %52.0 4.3 %
Same store sales increase (decrease): (12)
Total15.5 %8.8 %9.1 %10.4 %
Pharmacy19.5 %11.9 %12.1 %13.0 %
Front Store(1.1)%(2.2)%(2.5)%1.6 %
Prescription volume (6)
9.1 %2.7 %7.1 %3.7 %
Generic dispensing rate (6) (11)
88.2 %88.3 %89.5 %89.1 %
19

Supplemental Information
(Unaudited)

Corporate/Other segment

The following table summarizes the Corporate/Other segment’s performance for the respective periods:
Change
Three Months Ended
September 30,		Nine Months Ended
September 30,		Three Months Ended
September 30,
2024 vs 2023		Nine Months Ended
September 30,
2024 vs 2023
In millions, except percentages2024202320242023$%$%
Revenues:
Premiums $11 $12 $36 $38 $(1)(8.3)%$(2)(5.3)%
Services3 1 7 5 2 200.0 %2 40.0 %
Net investment income128 92 325 333 36 39.1 %(8)(2.4)%
Total revenues142 105 368 376 37 35.2 %(8)(2.1)%
Cost of products sold— — — 1 — — %(1)(100.0)%
Health care costs49 61 142 163 (12)(19.7)%(21)(12.9)%
Operating expenses449 507 1,539 1,538 (58)(11.4)%1 0.1 %
Restructuring charges
422 11 422 507 411 3,736.4 %(85)(16.8)%
Operating loss (778)(474)(1,735)(1,833)(304)(64.1)%98 5.3 %
Adjusted operating loss (1)
(329)(347)(996)(982)18 5.2 %(14)(1.4)%

20

Supplemental Information
(Unaudited)

The following table shows the components of the change in the consolidated health care costs payable during the nine months ended September 30, 2024 and 2023:
Nine Months Ended
September 30,
In millions20242023
Health care costs payable, beginning of the period$12,049 $10,142 
Less: Reinsurance recoverables5 5 
Less: Impact of discount rate on long-duration insurance reserves (a)
(23)8 
Health care costs payable, beginning of the period, net12,067 10,129 
Acquisitions, net— 1,098 
Add: Components of incurred health care costs
Current year85,541 64,183 
Prior years (b)
(845)(679)
Total incurred health care costs (c)
84,696 63,504 
Less: Claims paid
Current year71,356 52,952 
Prior years10,886 9,207 
Total claims paid82,242 62,159 
Health care costs payable, end of the period, net14,521 12,572 
Add: Premium deficiency reserve
670 — 
Add: Reinsurance recoverables65 4 
Add: Impact of discount rate on long-duration insurance reserves (a)
(19)(26)
Health care costs payable, end of the period$15,237 $12,550 
_____________________________________________
(a)Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive income (loss) on the unaudited condensed consolidated balance sheets.
(b)Negative amounts reported for incurred health care costs related to prior years result from claims being settled for amounts less than originally estimated.
(c)Total incurred health care costs for the nine months ended September 30, 2024 and 2023 in the table above exclude $70 million and $62 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets and $142 million and $163 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the unaudited condensed consolidated balance sheets. Total incurred health care costs for the nine months ended September 30, 2024 also exclude $670 million for premium deficiency reserves related to the Company’s Medicare, individual exchange and Medicaid product lines.


21

Endnotes

(1) The Company defines adjusted operating income as operating income (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, opioid litigation charges and losses on assets held for sale. The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from consolidated operating income in determining consolidated adjusted operating income.
(2) GAAP diluted earnings per share and Adjusted EPS, respectively, are calculated by dividing net income attributable to CVS Health and adjusted income attributable to CVS Health by the Company’s weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as acquisition-related transaction and integration costs, restructuring charges, office real estate optimization charges, opioid litigation charges, losses on assets held for sale, as well as the corresponding income tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health. See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from net income attributable to CVS Health in determining adjusted income attributable to CVS Health.
(3) Medical benefit ratio is calculated by dividing the Health Care Benefits segment’s health care costs by premium revenues and represents the percentage of premium revenues spent on medical benefits for the segment’s insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Health Care Benefits segment’s insured products.
(4) Medical membership represents the number of members covered by the Health Care Benefits segment’s insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on the Health Care Benefits segment’s total revenues and operating results.
(5) Pharmacy claims processed represents the number of prescription claims processed through the Company’s pharmacy benefits manager and dispensed by either its retail network pharmacies or the Company’s mail and specialty pharmacies. Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy & Consumer Wellness segment’s retail and long-term care pharmacies and infusion services operations. Management uses these metrics to understand variances between actual claims processed and prescriptions dispensed, respectively, and expected amounts as well as trends in period-over-period results. These metrics provide management and investors with information useful in understanding the impact of pharmacy claim volume and prescription volume, respectively, on segment total revenues and operating results.
(6) Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
(7) Days claims payable is calculated by dividing the Health Care Benefits segment’s health care costs payable at the end of each quarter by its average health care costs per day during such quarter. Management and investors use this metric as an indicator of the adequacy of the Health Care Benefits segment’s health care costs payable liability at the end of each quarter and as an indicator of changes in such adequacy over time.
22

(8) Gross profit is calculated as the segment’s total revenues less its cost of products sold, and, for the Health Services segment, health care costs. Gross margin is calculated by dividing the segment’s gross profit by its total revenues and represents the percentage of total revenues that remains after incurring direct costs associated with the segment’s products sold and services provided. Gross margin provides investors with information that may be useful in assessing the operating results of the Company’s Health Services and Pharmacy & Consumer Wellness segments.
(9) Health Services pharmacy network revenues relate to claims filled at retail and specialty retail pharmacies, including the Company’s retail pharmacies and LTC pharmacies, as well as activity associated with Maintenance Choice®, which permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.
(10) Health Services mail and specialty revenues relate to specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as mail order and specialty claims fulfilled by the Pharmacy & Consumer Wellness segment.
(11) Generic dispensing rate is calculated by dividing the segment’s generic drug claims processed or prescriptions filled by its total claims processed or prescriptions filled. Management uses this metric to evaluate the effectiveness of the business at encouraging the use of generic drugs when they are available and clinically appropriate, which aids in decreasing costs for client members and retail customers. This metric provides management and investors with information useful in understanding trends in segment total revenues and operating results.
(12) Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company’s retail pharmacy stores that have been operating for greater than one year and digital sales initiated online or through mobile applications and fulfilled through the Company’s distribution centers, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues and prescriptions from LTC and infusion services operations. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.
23
v3.24.3
Cover Page
Nov. 06, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Nov. 06, 2024
Entity Registrant Name CVS HEALTH CORP
Entity Central Index Key 0000064803
Amendment Flag false
Entity Incorporation, State or Country Code DE
Entity File Number 001-01011
Entity Tax Identification Number 05-0494040
Entity Address, Address Line One One CVS Drive
Entity Address, City or Town Woonsocket
Entity Address, State or Province RI
Entity Address, Postal Zip Code 02895
City Area Code 401
Local Phone Number 765-1500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol CVS
Security Exchange Name NYSE
Entity Emerging Growth Company false
CVS Health (NYSE:CVS)
過去 株価チャート
から 10 2024 まで 11 2024 CVS Healthのチャートをもっと見るにはこちらをクリック
CVS Health (NYSE:CVS)
過去 株価チャート
から 11 2023 まで 11 2024 CVS Healthのチャートをもっと見るにはこちらをクリック